85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details
臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-004447-23-GB (EUCTR) | 20/05/2019 | 15/03/2019 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial RESPIVANT RVT1601-cc-04 | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czech Republic;Canada;Belgium;Turkey;Australia;Netherlands;Germany;New Zealand;Italy;United Kingdom | ||
| 2 | EUCTR2016-003473-17-GB (EUCTR) | 14/09/2017 | 24/02/2017 | Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary Fibrosis | A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis | IDIOPATHIC PULMONARY FIBROSIS MedDRA version: 20.0;Level: LLT;Classification code 10067761;Term: Exacerbation of idiopathic pulmonary fibrosis;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: CC-90001 INN or Proposed INN: Not available | Celgene Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 210 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Taiwan;Greece;Turkey;Russian Federation;Colombia;United Kingdom;France;Canada;Brazil;Romania;Australia;Germany | ||
| 3 | NCT03142191 (ClinicalTrials.gov) | July 26, 2017 | 24/4/2017 | A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis | A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis;Fibrosis;Idiopathic Interstitial Pneumonias;Pathologic Processes;Lung Diseases, Interstitial;Lung Diseases;Respiratory Tract Diseases | Drug: CC-90001;Other: Placebo | Celgene | NULL | Completed | 40 Years | N/A | All | 138 | Phase 2 | United States;Australia;Brazil;Canada;Colombia;Germany;Greece;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United Kingdom;China |
| 4 | EUCTR2016-003473-17-GR (EUCTR) | 05/05/2017 | 02/03/2017 | Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary Fibrosis | A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis | IDIOPATHIC PULMONARY FIBROSIS MedDRA version: 20.0;Level: LLT;Classification code 10067761;Term: Exacerbation of idiopathic pulmonary fibrosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: CC-90001 | Celgene Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 135 | Phase 2 | United States;Taiwan;Greece;Turkey;Russian Federation;Colombia;United Kingdom;France;Canada;Brazil;Romania;Australia;Germany | ||
| 5 | NCT01203943 (ClinicalTrials.gov) | January 1, 2011 | 15/9/2010 | A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF) | A Phase 2 Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis;Pulmonary Fibrosis;Fibrosis;Interstitial Lung Disease;Lung Diseases, Interstitial | Drug: CC-930;Other: Placebo | Celgene | NULL | Terminated | 50 Years | N/A | All | 28 | Phase 2 | United States;Canada |
| 6 | NCT01135199 (ClinicalTrials.gov) | June 2010 | 28/5/2010 | Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis | Safety and Efficacy of Pomalidomide in the Treatment of Refractory Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study | Pulmonary Fibrosis | Drug: pomalidomide (CC-4047 | Stanford University | Celgene Corporation | Withdrawn | 18 Years | N/A | Both | 0 | Phase 2 | United States |
| 7 | EUCTR2006-002174-22-DE (EUCTR) | 08/11/2006 | 23/08/2006 | Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis - Inhaled Aviptadil in pulmonary fibrosis | Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis - Inhaled Aviptadil in pulmonary fibrosis | Pulmonary Fibrosis categorized as UIP or NSIP | Product Name: Aviptadil, 66 microgram/mL Other descriptive name: Vasoactive intestinal peptide | Mondobiotech Laboratories Anstalt | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Germany |